Aptamer inhibits SARS-CoV-2 with novel mechanism of action, study shows
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
Professor David Merryman explains how his team targeted the serotonin 2B receptor in animal models to preserve cardiac function six weeks after a heart attack.
Having revealed the activation mechanism and functional states of A2AR signalling, a GPCR, researchers say this could aid drug discovery.
A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
Researchers are using a new method to isolate the complex between SARS-CoV-2 and the ACE2 receptor to keep it embedded in the cell membrane.
Researchers have developed a cell-based assay for the discovery of new IDO1 inhibitors, overcoming challenges from cell-free assays.
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.
A novel machine learning method called DeepBAR could accelerate drug discovery and protein engineering, researchers say.
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
A team has discovered how enzymes control the formation of bioactive rubromycin-polyketides, which could be used to bioengineer new compounds.